{"groups":[{"description":"Lenalidomide 25 mg PI days 1-21 Cyclophosphamide 300 mg/m\\^2 PO days 1, 8, 15 Dexamethasone 40 mg PI days 1, 8, 15, 22","id":"FG000","title":"LCD (Cyclophosphamide 300 mg/m^2)"},{"description":"Lenalidomide 25 mg PI days 1-21 Cyclophosphamide 300 mg PO days 1, 8, 15 Dexamethasone 40 mg PI days 1, 8, 15, 22","id":"FG001","title":"LCD (Cyclophosphamide 300 mg)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"34"},{"groupId":"FG001","numSubjects":"19"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"34"},{"groupId":"FG001","numSubjects":"19"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Fifty-three (53) participants were recruited between July 2006 and August 2008 at Mayo Clinic."}